SynCore Biotechnology Co Ltd (4192) Fair Value & Analysis

Healthcare · TW · Market cap 682M TWD (≈ $21.6M) · ISIN TW0004192000

What is SynCore Biotechnology Co Ltd really worth?

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

• The price sits above even our optimistic bull case (7.29 TWD). The favourable scenario is already priced in.
• The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
• Solid but not exceptional quality (52/100) and above fair value, neither a clear bargain nor a standout compounder.
• A fairly wide model range (3.85 TWD to 7.29 TWD) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 29, 2026.

How to read this chart

60‑month range 18.50 TWD – 528.75 TWD · fair‑value band 3.85 TWD – 7.29 TWD · the 18.90 TWD price screens above the 5.84 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 29, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

SynCore Biotechnology Co Ltd (4192) currently trades at 18.90 TWD, while our model-based Fair Value estimate is 5.84 TWD, implying the stock looks roughly 223.6% overvalued today. The Quality Score stands at 52/100 (solid quality), in the Healthcare sector. How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Trailing-twelve-month revenue stands at 27.8M TWD. Revenue grew 13.7% year over year. It earns a return on equity of −17.6%. The balance sheet holds a net cash position of 263M TWD. Fundamentals as of Aug 29, 2026

Our scenario range runs from 3.85 TWD (bear case) to 7.29 TWD (bull case); at 18.90 TWD, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 36% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −56% fair-value upside, at −69%, 4192 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.

Key figures & financial health

Quality Score breakdown

About the company

SynCore Biotechnology Co.,Ltd, engages in development and sale of healthy food, medicine inspection, and biotechnology service in Taiwan.

Full company description

SynCore Biotechnology Co.,Ltd, engages in development and sale of healthy food, medicine inspection, and biotechnology service in Taiwan. The company is involved in the development of SB01, an injectable anti-cancer new ingredient (NCE) that is in Phase II clinical trials for the treatment of head and neck cancer; and SB02, an anti-cancer NCE, which is in preclinical research for use in the treatment of stomach cancer. It also offers SB03-Veregen, an ointment for the treatment of patients with external genital and perianal warts EGW; and SB04, a conventional drug for the treatment of age-related macular degeneration dry AMD that is in Phase II/III clinical trials. In addition, the company provides SB05-EndoTAG-1, a conventional drug for pancreatic cancer and triple-negative breast cancer that is in Phase III clinical trials. Further, it distributes cameras under the epiCam name such as hand-held color, hand-held monochrome, and veterinary fundus cameras that is used in recording the progress of ophthalmology diseases; and choroidal blood flow measurement. The company has partnerships with Aresus, MacuCLEAR Inc.; Y-YBAR; Epipole; and Sinphar Pharmaceutical Co., Ltd.; and The National Health Research Institutes NHRI. The company was incorporated in 2008 and is headquartered in Yilan City, Taiwan. SynCore Biotechnology Co.,Ltd operates as a subsidiary of Sinphar Pharmaceutical Co., Ltd.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

SynCore Biotechnology Co Ltd reported revenue of 27.0M TWD in FY2025 versus 6.9M TWD in FY2021, a compound +40.5%/yr. Reported net income was −45.8M TWD in FY2025.

4192 screens 224% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Peer Group

Biotechnology · 627 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Biotechnology median · lower = cheaper

Strength profile in five axes (Snowflake)

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Aug 29, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

Discover tools

Frequently asked questions